LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as the first three indications for its lead asset LBL-047 (DNTH212), a bifunctional fusion protein targeting pDC BDCA2 and inhibiting BAFF/APRIL. A two-part Phase 1 study in China was initiated in December 2025, with top-line results in healthy volunteers expected in the second half of 2026.
Key figures
- Deal Value Usd
- $1 billion
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.